JP Morgan Chase
CLRB icon

JP Morgan Chase’s Cellectar Biosciences CLRB Stock Holding History

JP Morgan Chase’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$24 – 7145
2025
Q1 		$24 Sell
3
-6,077
-100% -$55K ﹤0.01% 7092
2024
Q4 		$54.5K Buy
6,080
+5,308
+688% +$245K ﹤0.01% 5984
2024
Q3 		$49.6K Sell
772
-932
-55% -$61.5K ﹤0.01% 5992
2024
Q2 		$128K Buy
+1,704
New +$164K ﹤0.01% 5392
2024
Q1 		– Sell
-1
Closed -$55 – 7466
2023
Q4 		$55 Buy
+1
New +$74 ﹤0.01% 7193
2023
Q3 		– Hold
0
– – – 7099
2019
Q4 		– Sell
-35
Closed -$21K – 5625
2019
Q3 		$21K Buy
+35
New +$22.8K ﹤0.01% 5400

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

JP Morgan Chase's CLRB Position: Q2 2025 in Review

JP Morgan Chase sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 3 shares — an estimated $24 sold.

JP Morgan Chase first reported a position in CLRB in Q3 2019 and held it in 6 quarters. The position peaked at $128K in Q2 2024. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • JP Morgan Chase reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 3 Cellectar Biosciences shares in Q2 2025, an estimated $24.
  • JP Morgan Chase first reported a position in Cellectar Biosciences in Q3 2019 and held it in 6 quarters.
  • JP Morgan Chase's Cellectar Biosciences position peaked at $128K in Q2 2024.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.